For decades, cancer immunotherapy transformed the treatment of some blood cancers. But solid tumors—melanoma, lung cancer, colon cancer and many others—have often proved harder to penetrate. Their surroundings can suppress immune cells, hide cancer signals, and deprive attacking cells of the energy they need to keep fighting.
A treatment approved in the United States in 2024 offers a different way forward. Rather than giving patients a broadly engineered immune-cell product, doctors remove immune cells that have already found their way into a tumor, grow billions of them in a laboratory, and return them to the same patient.
The therapy, called lifileucel and marketed as Amtagvi, became the first U.S. Food and Drug Administration-approved cellular therapy for a solid tumor. Its initial approval is for adults with unresectable or metastatic melanoma whose disease has progressed after an immune checkpoint inhibitor and, when appropriate, a targeted therapy aimed at the BRAF mutation.
The decision does not mean that every patient responds, or that advanced melanoma has become easy to treat. It does mean that a patient’s existing immune response can sometimes be collected, expanded, and turned into a treatment when other options have run out.
Finding the immune cells already inside the tumor
The central idea behind tumor-infiltrating lymphocyte, or TIL, therapy is simple in outline. Tumors are not always immunologically invisible. In many cases, T cells have already entered the cancer and recognized something abnormal. The problem is that the number of these cells may be too small, or the tumor environment may prevent them from working effectively.
In TIL treatment, surgeons remove a piece of the patient’s tumor. Specialists then isolate the lymphocytes living in that tissue and test or grow them in the laboratory. Cells with the ability to recognize the cancer are expanded into a large population. The resulting product is not a universal medicine stored on a pharmacy shelf; it is made from the individual patient’s tumor and immune cells.
Before the cells are infused, patients receive chemotherapy to reduce some of their existing immune cells. This preparative treatment creates space for the expanded T cells. After the infusion, patients receive interleukin-2, a drug that helps stimulate the transferred cells but can also produce serious side effects.
The process is therefore more involved than a routine infusion. It requires surgery, specialized cell manufacturing, intensive chemotherapy, close monitoring, and access to a medical team experienced in managing complications. The treatment’s promise is inseparable from that complexity.
What the melanoma data showed
The FDA’s approval was based on results from a clinical study of lifileucel in people with advanced melanoma who had already received several therapies. In the group evaluated for the main response analysis, about 31.5 percent of patients experienced a measurable reduction in their tumors.
That figure is an overall response rate, not a guarantee for an individual patient. It includes partial and complete responses, and it does not mean that the remaining patients received no benefit or that every response lasted the same length of time. Cancer trials also measure patients at specific intervals, so the reported numbers describe the study population rather than the future experience of everyone treated.
Still, durability was one of the most encouraging features of the results. Among patients who responded, more than half had responses lasting at least six months at the time of the FDA’s review. Some responses continued beyond that period, although longer follow-up is needed to understand how often the treatment produces very long-term control.
The treatment was tested in a difficult clinical setting: patients had melanoma that had progressed after an anti-PD-1 therapy, a type of checkpoint inhibitor that is already one of the most important tools in modern melanoma care. Many had also received targeted treatment when their tumors carried a relevant BRAF mutation.
That context matters. A response after several standard therapies have failed can be clinically meaningful, even when it occurs in a minority of patients. It also explains why TIL therapy is currently used as a later-line option rather than a first treatment for most people with melanoma.
A different branch of cellular medicine
Lifileucel belongs to the expanding field of adoptive cell therapy. The best-known member of that family is CAR-T therapy, in which a patient’s T cells are genetically modified to recognize a selected target. CAR-T has produced striking results in several blood cancers, but solid tumors have presented different biological obstacles.
TIL therapy takes a less uniform approach. Instead of adding one engineered receptor, it returns a diverse population of T cells that came from the tumor itself. Those cells may recognize several cancer-related targets rather than a single marker. That diversity could be useful against tumors that vary from one region to another or change under treatment pressure.
But the approach also brings uncertainty. Not every tumor contains enough useful T cells. Cells that grow well in the laboratory may not be the strongest cells inside the body. The tumor’s physical structure and chemical environment can still suppress the immune response. Researchers are studying whether selecting particular T-cell populations, combining TILs with checkpoint inhibitors, or changing the manufacturing process can improve results.
Scientists are also investigating TIL therapy in cancers beyond melanoma, including cervical cancer, lung cancer, gastrointestinal cancers, and other solid tumors. These studies remain experimental unless a treatment has received regulatory approval for a particular use. Early results can be promising without establishing that a therapy works broadly across cancer types.
The treatment is powerful—and demanding
The risks of TIL therapy come from several parts of the treatment rather than from the infused cells alone. Chemotherapy used for lymphodepletion can lower blood counts and weaken the immune system, increasing the risk of infection and bleeding. The interleukin-2 given afterward can affect blood pressure, fluid balance, kidney function, breathing, and the heart.
Common or serious complications may include fever, chills, fatigue, low platelet and red blood cell counts, low levels of infection-fighting white blood cells, infections, and breathing or cardiovascular problems. Patients may need hospital care during the treatment period, and recovery can be difficult.
These risks make patient selection and treatment location important. A therapy that depends on surgery, individualized manufacturing, intensive supportive care, and a highly trained team cannot be separated from the health system required to deliver it. Access is likely to expand only as more hospitals gain the necessary infrastructure and as manufacturing becomes more predictable.
The individualized nature of the treatment also affects timing. A tumor sample must be collected, the cells must be grown and prepared, and the patient must remain well enough to receive the final product. Researchers are working to shorten manufacturing timelines and identify ways to make the process more consistent.
Why the approval matters beyond melanoma
The most important result may be conceptual. The approval shows that the immune cells found inside a solid tumor can be more than a sign of the body’s failed defense. Under the right conditions, they can become the raw material for a treatment.
That is a meaningful shift in cancer medicine. Earlier generations of immunotherapy mainly tried to remove the brakes from an existing immune response. TIL therapy adds another strategy: find the immune response already present, multiply it outside the body, and return it in a concentrated form.
The first approval also creates a regulatory and manufacturing path for future cellular treatments aimed at solid tumors. If researchers can determine which cells are most effective, improve their ability to survive in hostile tumor environments, and reduce the toxicity of the preparation process, the approach could become more practical and more broadly useful.
For now, lifileucel is neither a universal cancer cure nor a replacement for earlier treatments that work well for many people. Its significance is more measured: for some patients with advanced melanoma, it offers a new option after standard therapies have stopped controlling the disease. And for the wider field, it provides evidence that a solid tumor can be treated not only with a drug designed elsewhere, but with an immune response drawn from the patient’s own cancer and rebuilt into something stronger.
